Jang Woong Sik, Kim Sukyung, Podder Biswajit, Jyoti Md Anirban, Nam Kung-Woo, Lee Byung-Eui, Song Ho-Yeon
Regional Innovation Center, Soonchunhyang University, Asan 336-745, Republic of Korea.
Department of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan 330-090, Republic of Korea.
J Microbiol Biotechnol. 2015 Jun;25(6):946-50. doi: 10.4014/jmb.1412.12023.
Recently, it has become a struggle to treat tuberculosis with the current commercial antituberculosis drugs because of the increasing emergence of multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis. We evaluated here the antimycobacterial activity of tamoxifen, known as a synthetic anti-estrogen, against eight drug-sensitive or resistant strains of Mycobacterium tuberculosis (TB), and the active intracellular killing of tamoxifen on TB in macrophages. The results showed that tamoxifen had antituberculosis activity against drug-sensitive strains (MIC, 3.125-6.25 μg/ml) as well as drug-resistant strains (MIC, 6.25 to 12.5 μg/ml). In addition, tamoxifen profoundly decreased the number of intracellular TB in macrophages in a dose-dependent manner.
近年来，由于多重耐药（MDR）结核病和广泛耐药（XDR）结核病的日益出现，使用目前的商用抗结核药物治疗结核病已成为一项难题。我们在此评估了他莫昔芬（一种合成抗雌激素）对8株结核分枝杆菌（TB）敏感或耐药菌株的抗分枝杆菌活性，以及他莫昔芬在巨噬细胞中对结核杆菌的细胞内活性杀伤作用。结果表明，他莫昔芬对敏感菌株（MIC，3.125 - 6.25 μg/ml）和耐药菌株（MIC，6.25至12.5 μg/ml）均具有抗结核活性。此外，他莫昔芬以剂量依赖的方式显著减少了巨噬细胞内结核杆菌的数量。
